ALDX — Aldeyra Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $247.16m
- $119.49m
- 39
- 27
- 69
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 63.1 | 36.4 | 56.2 | 62.7 | 42.8 |
Operating Profit | -63.1 | -36.4 | -56.2 | -62.7 | -42.8 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -62.1 | -38 | -57.8 | -62 | -37.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -60.8 | -37.6 | -57.8 | -62 | -37.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -60.8 | -37.6 | -57.8 | -62 | -37.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -60.8 | -37.6 | -57.8 | -62 | -37.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2 | -1.05 | -1.07 | -1.06 | -0.637 |